Production (Stage)
NervGen Pharma Corp.
NGENF
$2.42
$0.19558.81%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.78% | -2.38% | 6.50% | -33.55% | 18.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.09% | 35.69% | 106.03% | 23.50% | 5.70% |
| Operating Income | -14.09% | -35.69% | -106.03% | -23.50% | -5.70% |
| Income Before Tax | -58.14% | 2.81% | -19.44% | -61.34% | 50.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.14% | 2.81% | -19.44% | -61.34% | 50.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.14% | 2.81% | -19.44% | -61.34% | 50.03% |
| EBIT | -14.09% | -35.69% | -106.03% | -23.50% | -5.70% |
| EBITDA | -14.71% | -35.83% | -107.84% | -24.11% | -5.67% |
| EPS Basic | -34.60% | 17.23% | -1.30% | -36.56% | 51.02% |
| Normalized Basic EPS | -34.25% | 17.32% | -1.48% | -36.63% | 50.95% |
| EPS Diluted | -34.60% | 17.23% | -1.30% | -36.56% | 51.02% |
| Normalized Diluted EPS | -34.25% | 17.32% | -1.48% | -36.63% | 50.95% |
| Average Basic Shares Outstanding | 17.37% | 17.50% | 17.93% | 18.13% | 2.11% |
| Average Diluted Shares Outstanding | 17.37% | 17.50% | 17.93% | 18.13% | 2.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |